Wills Financial Group Inc. increased its holdings in shares of Danaher Corporation (NYSE:DHR) by 7.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 30,339 shares of the conglomerate’s stock after acquiring an additional 2,204 shares during the quarter. Danaher comprises 1.9% of Wills Financial Group Inc.’s investment portfolio, making the stock its 18th biggest position. Wills Financial Group Inc.’s holdings in Danaher were worth $2,603,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of DHR. National Asset Management Inc. raised its stake in Danaher by 0.4% during the second quarter. National Asset Management Inc. now owns 3,767 shares of the conglomerate’s stock worth $318,000 after purchasing an additional 14 shares during the period. First Financial Corp IN raised its stake in Danaher by 0.8% during the second quarter. First Financial Corp IN now owns 2,720 shares of the conglomerate’s stock worth $230,000 after purchasing an additional 21 shares during the period. Brighton Jones LLC raised its stake in Danaher by 0.4% during the second quarter. Brighton Jones LLC now owns 5,159 shares of the conglomerate’s stock worth $435,000 after purchasing an additional 21 shares during the period. Buckingham Asset Management LLC raised its stake in Danaher by 0.4% during the second quarter. Buckingham Asset Management LLC now owns 5,778 shares of the conglomerate’s stock worth $488,000 after purchasing an additional 24 shares during the period. Finally, Simmons Bank raised its stake in Danaher by 0.4% during the second quarter. Simmons Bank now owns 7,160 shares of the conglomerate’s stock worth $604,000 after purchasing an additional 26 shares during the period. Hedge funds and other institutional investors own 76.32% of the company’s stock.

Shares of Danaher Corporation (NYSE:DHR) opened at $93.18 on Friday. The stock has a market cap of $64,816.47, a P/E ratio of 23.95, a PEG ratio of 2.22 and a beta of 1.02. Danaher Corporation has a 52 week low of $77.45 and a 52 week high of $94.82. The company has a quick ratio of 1.00, a current ratio of 1.43 and a debt-to-equity ratio of 0.42.

Danaher (NYSE:DHR) last released its quarterly earnings results on Thursday, October 19th. The conglomerate reported $1.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.05. The business had revenue of $4.53 billion for the quarter, compared to the consensus estimate of $4.47 billion. Danaher had a net margin of 13.36% and a return on equity of 11.29%. The business’s revenue was up 9.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.87 EPS. sell-side analysts anticipate that Danaher Corporation will post 3.99 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Stockholders of record on Friday, December 29th will be paid a $0.14 dividend. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.60%. The ex-dividend date is Thursday, December 28th. Danaher’s dividend payout ratio (DPR) is 16.52%.

A number of brokerages have commented on DHR. Goldman Sachs Group reaffirmed a “neutral” rating and set a $83.00 target price on shares of Danaher in a research note on Tuesday, September 26th. Robert W. Baird lifted their target price on shares of Danaher from $87.00 to $97.00 and gave the stock an “outperform” rating in a research note on Friday, October 20th. Cowen reaffirmed a “buy” rating and set a $90.00 target price on shares of Danaher in a research note on Wednesday, October 4th. Credit Suisse Group lifted their target price on shares of Danaher from $93.00 to $96.00 and gave the stock an “outperform” rating in a research note on Friday, October 20th. Finally, Morgan Stanley lifted their target price on shares of Danaher from $95.00 to $98.00 and gave the stock an “overweight” rating in a research note on Friday, October 20th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $93.31.

In related news, CEO Thomas Patrick Joyce, Jr. sold 125,989 shares of Danaher stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $92.64, for a total value of $11,671,620.96. Following the completion of the transaction, the chief executive officer now owns 271,737 shares in the company, valued at $25,173,715.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Robert S. Lutz sold 11,189 shares of Danaher stock in a transaction that occurred on Monday, October 23rd. The shares were sold at an average price of $91.66, for a total transaction of $1,025,583.74. Following the completion of the transaction, the chief accounting officer now owns 18,314 shares of the company’s stock, valued at approximately $1,678,661.24. The disclosure for this sale can be found here. Insiders sold a total of 273,810 shares of company stock worth $25,218,813 over the last three months. Insiders own 12.20% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Wills Financial Group Inc. Acquires 2,204 Shares of Danaher Corporation (DHR)” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/12/10/wills-financial-group-inc-acquires-2204-shares-of-danaher-corporation-dhr.html.

About Danaher

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Stock Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related stocks with our FREE daily email newsletter.